Regulatory Watch
Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022
regulatory Mar 2026

NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market

Read more
regulatory Mar 2026

29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list

Read more
regulatory Mar 2026

SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs

Read more
research Mar 2026

PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence

Read more
market Mar 2026

Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California

Read more
market Mar 2026

30+ clinic websites publishing reclassification articles — all financially conflicted, none independent

Read more
enforcement Mar 2026

BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone

Read more
enforcement Mar 2026

Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples

Read more
regulatory Mar 2026

MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion

Read more
enforcement Mar 2026

Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides'

Read more
enforcement Mar 2026

Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open

Read more
enforcement Mar 2026

All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture.

Read more
research Feb 2026

STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts

Read more
enforcement Nov 2025

Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief

Read more
enforcement Sept 2025

FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed

Read more
enforcement June 2025

FDA raids Amino Asylum warehouse; website goes offline, operations cease

Read more
regulatory Feb 2025

FDA declares semaglutide shortage resolved — compounding exception ends

Read more
regulatory Jan 2025

FDA eliminates Category 2/3 system; prohibited substances remain prohibited

Read more
market 2025

Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Read more
regulatory Dec 2024

PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604

Read more
regulatory Sept 2023

FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited

Read more

Stay Updated

Get enforcement alerts and regulatory updates in your inbox.

Subscribe to Newsletter